CA3036696A1 - Compositions with permeation enhancers for drug delivery - Google Patents
Compositions with permeation enhancers for drug delivery Download PDFInfo
- Publication number
- CA3036696A1 CA3036696A1 CA3036696A CA3036696A CA3036696A1 CA 3036696 A1 CA3036696 A1 CA 3036696A1 CA 3036696 A CA3036696 A CA 3036696A CA 3036696 A CA3036696 A CA 3036696A CA 3036696 A1 CA3036696 A1 CA 3036696A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- permeation enhancer
- certain embodiments
- combination
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Cephalosporin Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394716P | 2016-09-14 | 2016-09-14 | |
| US62/394,716 | 2016-09-14 | ||
| PCT/US2017/051577 WO2018053140A1 (en) | 2016-09-14 | 2017-09-14 | Compositions with permeation enhancers for drug delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3036696A1 true CA3036696A1 (en) | 2018-03-22 |
Family
ID=61619716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3036696A Pending CA3036696A1 (en) | 2016-09-14 | 2017-09-14 | Compositions with permeation enhancers for drug delivery |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200138710A1 (enExample) |
| EP (1) | EP3512501A4 (enExample) |
| JP (1) | JP7277360B2 (enExample) |
| KR (1) | KR20190053215A (enExample) |
| CN (2) | CN109937033A (enExample) |
| AU (1) | AU2017326347B2 (enExample) |
| CA (1) | CA3036696A1 (enExample) |
| WO (1) | WO2018053140A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016304585B2 (en) | 2015-08-05 | 2023-04-06 | Children's Medical Center Corporation | Compositions with permeation enhancers for drug delivery |
| WO2022031577A1 (en) * | 2020-08-03 | 2022-02-10 | Children's Medical Center Corporation | Thermo-sensitive permeation enhancing formulations for drug delivery |
| EP3949956A1 (en) * | 2020-08-06 | 2022-02-09 | LTS Lohmann Therapie-Systeme AG | Esketamine-suspension-tts |
| GB202100945D0 (en) * | 2021-01-25 | 2021-03-10 | Brightcure Ltd | A composition useful for treating bacterial infections |
| DE102021132055B4 (de) | 2021-10-08 | 2024-12-12 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mit beschränkter Haftung | Neue Therapiekonzepte für die Behandlung von Otitis |
| CN117618338A (zh) * | 2022-08-16 | 2024-03-01 | 海南普利制药股份有限公司 | 一种稳定的奥利万星药物水溶液及其制备方法 |
| CN118518439B (zh) * | 2023-02-17 | 2025-09-16 | 清华大学 | 离子液体制剂和组织处理方法及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996006597A1 (en) * | 1994-08-30 | 1996-03-07 | Alcon Laboratories, Inc. | Thermally-gelling ophthalmic drug delivery vehicles containing cellulose ethers |
| WO2000007603A2 (en) * | 1998-08-04 | 2000-02-17 | Madash Llp | End modified thermal responsive hydrogels |
| JP4822652B2 (ja) * | 2000-11-22 | 2011-11-24 | エンド ファーマシューティカルズ インコーポレイテッド | 粘膜炎の治療 |
| US7220431B2 (en) * | 2002-11-27 | 2007-05-22 | Regents Of The University Of Minnesota | Methods and compositions for applying pharmacologic agents to the ear |
| US9056061B2 (en) * | 2005-09-23 | 2015-06-16 | Alza Corporation | Transdermal nicotine salt delivery system |
| WO2009142719A2 (en) * | 2008-05-19 | 2009-11-26 | Massachusetts Institute Of Technology | Tympanic membrane permeating ear drops and uses thereof |
| CN106344495A (zh) * | 2008-12-22 | 2017-01-25 | 奥德纳米有限公司 | 用于治疗耳部病症的控制释放耳感觉细胞调节剂组合物 |
| AU2016304585B2 (en) * | 2015-08-05 | 2023-04-06 | Children's Medical Center Corporation | Compositions with permeation enhancers for drug delivery |
-
2017
- 2017-09-14 WO PCT/US2017/051577 patent/WO2018053140A1/en not_active Ceased
- 2017-09-14 KR KR1020197010227A patent/KR20190053215A/ko not_active Withdrawn
- 2017-09-14 CA CA3036696A patent/CA3036696A1/en active Pending
- 2017-09-14 CN CN201780069720.5A patent/CN109937033A/zh active Pending
- 2017-09-14 EP EP17851534.2A patent/EP3512501A4/en active Pending
- 2017-09-14 US US16/333,368 patent/US20200138710A1/en active Pending
- 2017-09-14 CN CN202510689336.1A patent/CN120392650A/zh active Pending
- 2017-09-14 JP JP2019514312A patent/JP7277360B2/ja active Active
- 2017-09-14 AU AU2017326347A patent/AU2017326347B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109937033A (zh) | 2019-06-25 |
| WO2018053140A1 (en) | 2018-03-22 |
| US20200138710A1 (en) | 2020-05-07 |
| CN120392650A (zh) | 2025-08-01 |
| KR20190053215A (ko) | 2019-05-17 |
| EP3512501A1 (en) | 2019-07-24 |
| JP2019533644A (ja) | 2019-11-21 |
| AU2017326347B2 (en) | 2023-07-20 |
| AU2017326347A1 (en) | 2019-03-21 |
| JP7277360B2 (ja) | 2023-05-18 |
| EP3512501A4 (en) | 2020-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12053527B2 (en) | Compositions with permeation enhancers for drug delivery | |
| AU2017326347B2 (en) | Compositions with permeation enhancers for drug delivery | |
| JP7033789B2 (ja) | トリグリセリド耳用製剤とその使用 | |
| RU2675360C2 (ru) | Способы лечения местных микробных инфекций | |
| CN110420211A (zh) | 治疗炎症、自身免疫性疾病和疼痛的方法 | |
| US20110166060A1 (en) | Tympanic membrane permeating ear drops and uses thereof | |
| US20190365906A1 (en) | Random copolymer therapeutic agent carriers and assemblies thereof | |
| JP2024170397A (ja) | 薬物送達のための相乗的な透過促進剤を伴う組成物 | |
| WO2020072602A1 (en) | Pharmaceutical compositions comprising otic therapeutic agents and related methods | |
| US20260091049A1 (en) | Halide-free ammonium silanes | |
| CA3188400A1 (en) | Thermo-sensitive permeation enhancing formulations for drug delivery | |
| WO2025212563A1 (en) | Injectable hydrogel based on liposome self-assembly for sustained release of small hydrophilic molecules | |
| HK40078560A (en) | Antimicrobial organosilanes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220817 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240906 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240906 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240906 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241017 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250117 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250520 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250520 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250905 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250905 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260326 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260326 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20260418 |